Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-07 5:33 pm Sale | 2024-03-07 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 66,719,779 8.280% | -45,821,757 (-40.72%) | Filing History |
| 2024-02-14 4:46 pm Unchanged | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Ramaswamy Vivek | 81,454,521 9.750% | 0 (Unchanged) | Filing History |
| 2024-02-14 11:14 am Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 112,541,536 13.970% | -10,000,000 (-8.16%) | Filing History |
| 2024-02-14 10:20 am Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | VIKING GLOBAL INVESTORS LP | 69,368,961 8.600% | -5,869,739 (-7.80%) | Filing History |
| 2024-02-14 06:51 am Unchanged | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% | 0 (Unchanged) | Filing History |
| 2024-02-13 5:26 pm Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Ramaswamy Vivek | 81,454,521 9.750% | -328,720 (-0.40%) | Filing History |
| 2024-02-13 5:00 pm Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | SB INVESTMENT ADVISERS (UK) LTD | 73,031,667 9.100% | -22,000,000 (-23.15%) | Filing History |
| 2024-02-01 5:24 pm Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Sumitomo Chemical Co. Ltd. | 71,251,083 8.860% | -15,116,277 (-17.50%) | Filing History |
| 2023-10-04 5:19 pm Purchase | 2023-10-02 | 13D | Immunovant, Inc. IMVT | Roivant Sciences Ltd. ROIV | 79,815,331 55.300% | 6,416,667 (+8.74%) | Filing History |
| 2023-06-26 5:05 pm Sale | 2023-06-22 | 13G | Roivant Sciences Ltd. ROIV | VIKING GLOBAL INVESTORS LP | 75,238,700 9.900% | -13,000,000 (-14.73%) | Filing History |
| 2023-02-14 5:20 pm Purchase | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | Ramaswamy Vivek | 81,783,241 10.900% | 7,381,272 (+9.92%) | Filing History |
| 2023-02-14 4:08 pm Purchase | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 14.150% | 4,040,285 (+4.09%) | Filing History |
| 2023-02-14 4:08 pm Sale | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | SB INVESTMENT ADVISERS (UK) LTD | 95,031,667 13.100% | -4,343,919 (-4.37%) | Filing History |
| 2023-02-14 11:46 am Sale | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 122,541,536 16.890% | -6,852,281 (-5.30%) | Filing History |
| 2023-02-03 4:30 pm Unchanged | 2022-12-31 | 13G | Roivant Sciences Ltd. ROIV | Sumitomo Chemical Co. Ltd. | 86,367,360 11.910% | 0 (Unchanged) | Filing History |
| 2022-02-14 5:01 pm Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | VIKING GLOBAL INVESTORS LP | 88,238,700 12.800% | 88,238,700 (New Position) | Filing History |
| 2022-02-14 4:01 pm Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | Ramaswamy Vivek | 74,401,969 10.500% | 74,401,969 (New Position) | Filing History |
| 2022-02-14 3:00 pm Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 129,393,817 18.700% | 129,393,817 (New Position) | Filing History |
| 2022-02-14 09:57 am Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | SB INVESTMENT ADVISERS (UK) LTD | 99,375,586 14.400% | 99,375,586 (New Position) | Filing History |
| 2022-02-10 4:26 pm Purchase | 2021-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 98,809,158 14.280% | 98,809,158 (New Position) | Filing History |